Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunct therapy in adults with partial-onset seizures. It was discovered by researchers at Dainippon Sumitomo Pharma (大日本住友製薬: Dainippon Sumitomo Seiyaku (formerly Dainippon Pharmaceutical (大日本製薬: Dainippon Seiyaku)), who launched it in 1989 as Excegran® in Japan. It was marketed by Élan in the United States starting in 2000 as Zonegran®, before Élan transferred their interests in zonisamide to Eisai (エーザイ) in 2004. Eisai also markets Zonegran® in Asia (China, Taiwan, and fourteen others) and Europe (starting in Germany and the United Kingdom).
It has also been studied for obesity | url = http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&list_uids=12684361&dopt=ExternalLink}} with significant positive effects on body weight and there are three ongoing clinical trials for this indication.,,
More on [ Zonisamide ]

Zonegran (Zonisamide) Capsules: Newly Approved Drug Therapies - Profile prepared at the time of US FDA approval, from CenterWatch Clinical Trials Listing Service. Discusses uses, results of clinical testing, side effects, and mechnisms of action.
Meta Description: [ Listing for Zonegran (zonisamide) Capsules in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service ]
Zonisamide - Medline Plus - Information for consumers including proper use, precautions, and storage recommendations.
Meta Description: [ Zonisamide(Systemic) ]